TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects between 18 and 75 years of age.~2. Moderate to severe plaque-type psoriasis for at least 6 months.~3. Subject is a candidate for systemic biologic therapy.~4. Subject has IGA ≥3, involved body surface area (BSA) ≥10%, and PASI ≥12 at screening and at baseline.~5. Subject is able to comply with the study procedures.~6. Subject must provide informed consent.~Exclusion Criteria (Main):~1. Non-plaque type psoriasis, drug-induced psoriasis, or other skin conditions (e.g., eczema). (Psoriatic arthritis is allowed).~2. Other medical conditions, including planned surgery or active infection / history of infection, as defined in the study protocol. Subjects will be screened for tuberculosis and hepatitis B / hepatitis C.~3. Laboratory abnormalities at screening, as defined in the study protocol.~4. Prior use of systemic or topical treatments for psoriasis, as defined in the study protocol.~5. Prior use of any compound targeting IL-17, more than two biologic therapies, ustekinumab within 6 months, or TNF targeting therapies within 12 weeks.~6. History of suicidal thoughts within 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- M1095 (Sonelokimab) 30mg (Type: EXPERIMENTAL): M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
- M1095 (Sonelokimab) 60mg (Type: EXPERIMENTAL): M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
- M1095 (Sonelokimab) 120mg - regimen 1 (Type: EXPERIMENTAL): M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
- M1095 (Sonelokimab) 120mg - regimen 2 (Type: EXPERIMENTAL): M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
- Placebo / M1095 (Sonelokimab) 120mg (Type: PLACEBO_COMPARATOR): Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
- Secukinumab (Type: ACTIVE_COMPARATOR): Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of severe intrauterine adhesions~* infertility~Exclusion Criteria:~* endometrial tuberculosis~* grossly abnormal semen analysis~* ovarian failure, hydrosalpinx fluid~* patients who did not proceed to second-look hysteroscopy within the specified time frame~* Women with no desire to pregnancy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
- Group B (Type: EXPERIMENTAL): At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with vasomotor symptoms with a uterus who are postmenopausal or in late menopause transition~* Body Mass Index (BMI) \<36 kg/m2~* Class I-III mammogram within 6 months of Random Periareolar Fine Needle Aspiration (RPFNA); If Class 0 or 4, must be resolved with additional procedures~* If previously on oral contraceptives or hormone replacement, off for 8 weeks or more prior to baseline RPFNA; the exception is low dose vaginal hormones~* Confirmed moderate risk of developing breast cancer~* RPFNA results within study defined range~* Kidney and liver function within study defined range~* Willing and able to comply with study related procedures~Exclusion Criteria:~* Previous biopsy showing evidence of breast cancer~* Have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke~* History of renal or liver disease~* Prior ovarian or endometrial cancer~* Stopped or started hormone replacement within 8 weeks~* Any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for RPFNA~* Currently taking or have taken specific medications in the past 6 months~* Participation on any chemoprevention trial within 6 months~* Current illness which would make potential participant unsuitable for enrollment

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 61 Years
- Healthy Volunteers: f

Study Arms:
- Duavee (Type: EXPERIMENTAL): Participants will be asked to take Duavee for 6 months while on the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients with progressive or relapsing motor and sensory dysfunction of more than one limb resulting from neuropathy within 2 months prior to the date informed consent is obtained.~* 2. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the INCAT score of 2 must be exclusively from leg disability to qualify.)~* 3. Patients who need high-dose intravenous immunoglobulin therapy.~* 4. Patients who continued treatment for CIDP without addition or increase at 30 days before informed consent.~* 5. Patients with greater than or equal to twenty years old at informed consent.~Exclusion Criteria:~* 1. Patients with evidence of myelopathy or demyelination of central nerve~* 2. Patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes（diabetic neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy）~* 3. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, malignancy, vasculitis, Crow-Fukase syndrome, Sjögren syndrome.~* 4. Patients with multifocal motor neuropathy.~* 5. Patients treated with plasmapheresis at 3 months before informed consent.~* 6. Patients treated with rituximab at 6 months before informed consent.~* 7. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.~* 8. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.~* 9. Patients with history of shock or hypersensitivity for NPB-01.~* 10. Patients with IgA deficiency.~* 11. Patients with malignancy at informed consent.~* 12. Patients with impaired liver function.~* 13. Patients with impaired renal function.~* 14. Patients with cerebro- or cardiovascular disorders.~* 15. Patients with high risk of thromboembolism.~* 16. Patients with hemolytic/hemorrhagic anemia.~* 17. Patients with decreased cardiac function.~* 18. Patients with decreased platelet.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- NPB-01 (Type: EXPERIMENTAL): Intravenous immunoglobulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke at least 10 cigarettes per day for the previous 6 months - Expired CO \> 9 ppm - Motivated to quit smoking - Able to read and write English - Willing to complete required study assessments~Exclusion Criteria:~* Uncontrolled hypertension (systolic \>180mm Hg or diastolic \>110mm Hg) - History of bipolar disorder or psychosis - Myocardial infarction or other serious cardiac problem in the previous 4 weeks - History of diagnosed anorexia and/or bulimia - Diagnosis of Alcohol Dependence in the previous 6 months by participant self-report or drinking 6 or more drinks on six or more days a week - History of seizure and/or serious head injury involving loss of consciousness - Use of contraindicated medications (MAO inhibitors, bupropion, lithium, anticonvulsants, antipsychotics) - Currently pregnant or breast-feeding - Unwilling to use effective contraception during the treatment phase - More than one participant from the same household - Allergic reactions to 3 or more classes of drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): nicotine patch alone treatment
- 2 (Type: EXPERIMENTAL): nicotine lozenge alone treatment
- 3 (Type: EXPERIMENTAL): nicotine patch + lozenge combination treatment
- 4 (Type: EXPERIMENTAL): bupropion alone treatment
- 5 (Type: EXPERIMENTAL): bupropion + nicotine lozenge combination treatment
- 6 (Type: PLACEBO_COMPARATOR): placebo control (no active medication) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD according to GOLD guidelines, and current COPD symptoms~* A current or previous smoking history equivalent to 10 or more packs per year (1 pack year = 20 cigarettes smoked per day for one year).~* Documented use of a short-acting inhaled bronchodilator (β2-agonist or anticholinergics) as reliever medication.~Exclusion Criteria:~* A history and/or current diagnosis of asthma.~* Patients who have experienced COPD exacerbation requiring hospitalisation and/or a course of antibiotics and/or a course of systemic steroid within 30 days (from end of exacerbation treatment) prior to Visit 1 and/or during the run-in period.~* A history and/or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Formoterol, then Salmeterol, then Placebo (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
- Salmeterol, then Palcebo, then Formoterol (Type: EXPERIMENTAL): Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
- Placebo, then Formoterol, then Salmeterol (Type: EXPERIMENTAL): Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
- Formoterol, then Placebo, then Salmeterol (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
- Salmeterol, then Formoterol, then Placebo (Type: EXPERIMENTAL): Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
- Placebo, then Salmeterol, then Formoterol (Type: EXPERIMENTAL): Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes Mellitus~* Diabetic Nephropathy~* Glomerular filtration rate \> 30 ml/min/1.73 m2~* Blood pressure \> 130/80 mm Hg~Exclusion Criteria:~* Child bearing potential~* Plasma-potassium \>4.5 mmol/l~* Breastfeeding~* Abuse of alcohol or drugs~* Non-diabetic kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 to 60 years~2. Body mass index 20 kg/m2 to 25 kg/m2~3. Hemoglobin above 130g/L.~4. Normal glucose tolerance in response to a 75g, 2-hr OGTT~Exclusion Criteria:~1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.~2. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 100 or systolic \> 180) or proliferative retinopathy~3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.~4. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.~5. Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH \> 6 mU/l~6. Current addiction to alcohol or substances of abuse as determined by the investigator.~7. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation~8. Taking any prescription or non-prescription medications at the time of the study~9. Having donated blood three months prior to and three months post study procedures~10. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.~11. No clinical evidence of neoplasms which have been known to overexpress GLP-1 receptors i.e. pheochromocytomas, brain tumors and embryonic tumors.~12. Hypersensitivity to egg-, soya-,or peanut protein or previous allergy to intralipid~13. Those with known sensitivity to metoclopramide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- exenatide subcutaneous injection (Type: EXPERIMENTAL): Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mycotic Ulcer Treatment Trial I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of a corneal ulcer at presentation~* Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)~* Visual acuity between 6/12 (20/40, logMAR 0.3) and 6/120 (20/400, logMAR 1.3)~* The patient must be able to verbalize a basic understanding of the study after it is explained to the patient, as determined by physician examiner. This understanding must include a commitment to return for follow-up visits.~* Willingness to be treated as an inpatient or to be treated as an outpatient and return every 3 days +/- 1 day until re-epithelialization and every week to receive fresh medication for 3 weeks~* Appropriate consent~Exclusion Criteria:~* Impending perforation~* Evidence of bacteria on Gram stain at the time of enrollment~* Evidence of acanthamoeba by stain~* Evidence of herpetic keratitis by history or exam~* Corneal scar not easily distinguishable from current ulcer~* Age less than 16 years (before 16th birthday)~* Bilateral ulcers~* Previous penetrating keratoplasty in the affected eye~* Pregnancy (by history or urine test) or breast feeding (by history)~* Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)~* Acuity worse than 6/120 (20/400) or better than 6/12 (20/40) in the study eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA can be used for enrollment)~* Known allergy to study medications (antifungal or preservative)~* No light perception in the affected eye~* Not willing to participate

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Natamycin (Type: ACTIVE_COMPARATOR): None
- Topical Voriconazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* COPD~* Current or exsmokers, 10 pack years~Exclusion Criteria:~* Asthma~* Any clinically relevant abnormal findings at screening examinations~* Recent COPD exacerbation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD3199 low dose
- 2 (Type: EXPERIMENTAL): AZD3199 intermediate dose
- 3 (Type: EXPERIMENTAL): AZD3199 high dose
- 4 (Type: ACTIVE_COMPARATOR): Formoterol 2x4.5 microgram bid
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary RLS, based on the International RLS Study Diagnostic Criteria.~Exclusion Criteria:~* A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS;~* Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's Disease, Multiple Sclerosis, dyskinesias, and dystonias);~* Abnormal laboratory results, electrocardiogram (ECG) or physical findings;~* Pregnant or lactating women;~* Women of childbearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XP13512 600MG (Type: EXPERIMENTAL): XP13512 600MG ONCE DAILY
- XP13512 1200MG (Type: EXPERIMENTAL): XP13512 1200MG ONCE DAILY
- Placebo (Type: PLACEBO_COMPARATOR): PLACEBO ONCE DAILY

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete